Interactive Investor
>>

BeiGene Ltd ADR (NASDAQ:BGNE) Share Price

BGNE

BeiGene Ltd ADR

North American company

Right Arrow 1

Healthcare

Right Arrow 2

Biotechnology

Bid

-

Ask

-

Last Traded

-

Chg

-

-

XNAS

-

Updated: -

Research

News & analysis

Loading...

Times are shown in GMT-4, values are delayed by at least 15 minutes. Past performance is not a reliable indicator of future results.

Company Profile

BeiGene Ltd is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1.BeiGene Ltd is a biopharmaceutical company engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. Its product includes BGB-3111, BGB-A317 and BGB-290 and one immuno-oncology agent.

NASDAQ:BGNE

US07725L1026

USD

Loading...

Loading Comparison

Latest BGNE News